Dave Alden's practice focuses on product liability and, in particular, on actions involving pharmaceuticals, medical devices, tobacco, and consumer products. He also has substantial experience defending accounting malpractice, RICO, and securities actions. Dave has been involved in multiple trials and appeals in state and federal courts. He regularly counsels clients regarding privilege and work product issues, including Ohio's attorney-client privilege statute, which was amended in 2013 as first advocated in Dave's 2011 law review article.

For years, Dave has represented clients as national coordinating counsel, including R.J. Reynolds in smoking and health actions and Wyeth in actions involving prescription antidepressants. He recently represented Bayer in an arbitration in which Recoly challenged Bayer discontinuing development of a hemophilia product, and Recoly's claims were denied. Dave previously was in-house counsel at a major accounting firm.

Dave coauthored Drug and Device Product Liability Litigation Strategy (Oxford Univ. Press 2012); the Ohio chapter in Product Liability Desk Reference: A Fifty-State Compendium (Wolters Kluwer 2014); "Voluntary Client Testimony As A Privilege Waiver: Is Ohio's Law Caught In A Time Warp?," 59(1) Clev. St. L. Rev. 1 (2011); and "The Meaning Of The Parallel Requirements Exception Under Lohr and Riegel," 65(3) N.Y.U. Ann. Surv. Am. L. 545 (2010). His pro bono representations include Raymond Towler, who was exonerated by new DNA test results in 2010 after 29 years in prison, and Douglas Prade, who is seeking a new trial after he was excluded from male DNA found over where the murderer bit the victim.